Lifevantage (LFVN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Lifevantage (LFVN) is set to announce its Q4 2025 earnings on August 27, 2025, with analysts predicting earnings of $0.17 per share and revenue of approximately $57.93 million.
• Shares of Lifevantage opened at $13.09, showing a 4.4% decline, with a 1-year price range between $7.09 and $27.38.
• Insider activity indicates CFO Carl Aure sold 2,746 shares at an average price of $13.39, reducing his holding by 2.02%, and 20.65% of the stock is currently owned by company insiders.

Lifevantage (NASDAQ:LFVN - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Thursday, September 4th. Analysts expect Lifevantage to post earnings of $0.17 per share and revenue of $57.9310 million for the quarter. Investors can check the company's upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Thursday, September 4, 2025 at 4:30 PM ET.

Lifevantage Stock Performance

Shares of Lifevantage stock traded up $0.51 on Friday, reaching $13.08. The company had a trading volume of 124,264 shares, compared to its average volume of 82,717. The firm's 50 day moving average price is $13.02 and its two-hundred day moving average price is $14.02. Lifevantage has a 52-week low of $7.09 and a 52-week high of $27.38. The firm has a market cap of $164.68 million, a PE ratio of 18.96 and a beta of 0.45.

Insider Transactions at Lifevantage

In other Lifevantage news, CFO Carl Aure sold 2,746 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $13.39, for a total value of $36,768.94. Following the sale, the chief financial officer owned 133,303 shares of the company's stock, valued at $1,784,927.17. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.65% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lifevantage

Institutional investors and hedge funds have recently modified their holdings of the company. Evergreen Capital Management LLC acquired a new position in shares of Lifevantage in the second quarter valued at approximately $379,000. Wasatch Advisors LP grew its stake in shares of Lifevantage by 6.6% in the second quarter. Wasatch Advisors LP now owns 446,341 shares of the company's stock worth $5,838,000 after acquiring an additional 27,765 shares in the last quarter. Man Group plc increased its position in shares of Lifevantage by 72.5% during the second quarter. Man Group plc now owns 53,098 shares of the company's stock worth $695,000 after acquiring an additional 22,319 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Lifevantage by 2,555.8% in the second quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company's stock valued at $80,000 after acquiring an additional 5,904 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Lifevantage by 19.6% in the second quarter. Bank of America Corp DE now owns 33,376 shares of the company's stock valued at $437,000 after purchasing an additional 5,472 shares during the period. Hedge funds and other institutional investors own 35.32% of the company's stock.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.